Background-Mutations in the MEF2A gene, coding for a member of the myocyte enhancer factor 2 family of transcription factors, have been reported in patients with coronary artery disease and myocardial infarction (MI). In particular, a 21-bp deletion and 3 missense mutations were demonstrated either to reduce MEF2A transcriptional activity or to impair its nuclear translocation. However, the association of MEF2A with coronary artery disease/MI was not confirmed in other studies. We analyzed the role of MEF2A in the pathogenesis of MI in 2008 Italian patients with premature MI and in 2008 controls. Methods and Results-Mutational screening of exon 8 (containing all so-far reported point mutations) disclosed 5 novel and 2 previously described missense mutations. Microsatellite genotyping and sequencing revealed the presence of the 21-bp deletion (located in exon 12) in 5 cases and in none of the controls. Functional studies on mutant proteins showed no alteration, neither in the transactivating properties (all mutants) nor in the nuclear localization (21-bp deletion). Furthermore, an association analysis performed using 3 microsatellites at the MEF2A locus showed no significant association with MI. These results were confirmed in a replication study performed on an independent Italian population with coronary artery disease. Conclusions-All together, our data do not support MEF2A as a susceptibility gene for coronary artery disease/MI in the Italian population. (Circ Cardiovasc Genet. 2009;2:165-172.) 
wide association studies. The first promising results of this approach, among several additional loci, pointed the attention to a region on chromosome 9p21.3, which was initially found to be associated with CAD/MI in the Icelandic, 4 Canadian, 5 English, and German 6, 7 populations and represents the most highly replicated locus for CAD/MI identified to date.
The study of the genetic basis of complex diseases may also take advantage from the rare occurrence of autosomal dominant forms of the disease in single families. This approach identified the MEF2A gene, a member of the myocyte enhancer factor 2 (MEF2) family of MADS-box transcription factors, as the gene responsible for an autosomal dominant form of CAD in a single large family. 8 A genomewide linkage scan indicated significant linkage to a single locus on chromosome 15q26. Among the 93 genes annotated in this region, MEF2A became the foremost candidate gene, because of its known effects on myocardial development and vascular morphogenesis. 8 The MEF2A gene, located at chromosome 15q26.3, is composed of 12 exons spread over Ϸ115 kb (http://genome.ucsc.edu, release March 2006), 9 and is expressed at high levels in skeletal, cardiac, smooth muscles, neuronal cells, and in the endothelium of coronary arteries. 8, 10 Wang et al, 8 resequencing MEF2A, disclosed a 21-bp deletion in the last exon of the gene, which was present in all affected members of the analyzed CAD family. The same 21-bp deletion was absent either in the unaffected family members or in the 119 controls with normal angiograms. Moreover, in vitro expression of the mutant protein indicated that the predicted 7-amino acid deletion (⌬7aa) causes a block of MEF2A entry into the nucleus and an impairment of its transcriptional activity by a dominant-negative mechanism. 8 Subsequent studies by the same research group in Ͼ400 cases with MI and controls revealed 3 additional missense mutations (Asn263Ser, Pro279Leu, and Gly283Asp) in exon 8 of MEF2A (often reported as exon 7 in previous articles). These mutations, found in 1.9% of cases but not in controls, 11 were suggested to reduce the transcriptional activity of MEF2A by a loss-of-function mechanism, thus playing a substantial role in the development of CAD. Nonetheless, the role of MEF2A in the pathogenesis of cardiovascular diseases still remains uncertain; in fact, several case-control studies have been undertaken, but controversial results were found. [12] [13] [14] [15] [16] [17] Moreover, a recent study by Lieb et al 18 performed on more than 1700 patients with MI, 2 large control populations, and extended families with apparently Mendelian inheritance of the disease showed no evidence of association between MEF2A and MI.
In this study, we analyzed the role of MEF2A in the pathogenesis of CAD/MI in 2 Italian populations by a combined approach based on mutational screening, association analysis, and functional characterization of identified MEF2A variants. Our analyses substantially do not support the role of MEF2A as a susceptibility gene for CAD/MI.
Methods

Materials
Expression plasmids used in this study have been obtained as follows: (1) the pcDNA3.1-MEF2A vector, containing the fulllength MEF2A cDNA, was a gift from Prof Qing Wang (Cleveland Clinic Foundation, Cleveland, Ohio); (2) the pE-MEF2A-GFP and ⌬NLS-MEF2A-GFP vectors, containing the full-length MEF2A cDNA C-terminally fused to the green fluorescent protein (GFP) (the ⌬NLS version presenting a 36-bp deletion including the nuclear localization signal, NLS), were provided by Prof Stefano Ferrari (Department of Biomedical Sciences, University of Modena and Reggio Emilia, Italy); (3) the pcDNA3.1-MEF2A-FLAG vector, containing the full-length MEF2A cDNA tagged at the C-terminus with a FLAG epitope, was a gift from Prof Eric N. Olson's laboratory (Department of Molecular Biology, University of Texas Southwestern Medical Center at Dallas, Dallas, Tex); (4) the 4xMEF2A-Luc plasmid, having 4 copies of the MEF2-binding site upstream of the c-jun minimal promoter, directing the transcription of the firefly luciferase gene, was a gift from Prof John McDermott (York University, Toronto, Canada); (5) the pRL-TK plasmid, encoding renilla luciferase under the control of HSV thymidine kinase promoter, was purchased from Promega (Madison, Wis); and (6) the pTARGET mammalian expression vector was from Promega.
All oligonucleotide primer couples used for mutational screening, mutagenesis experiments, and for microsatellite analysis were synthesized from Sigma (St Louis, Mo); the complete list is reported in the online-only Data Supplement Table I. The sources of the antibodies were as follows: (1) mouse anti-FLAG M2 antibody (catalogue number F3165) from Sigma and (2) Alexa Fluor 568-conjugated goat antimouse IgG (catalogue number A11004) from Molecular Probes (Invitrogen, Carlsbad, Calif).
Study Population
The institutional review boards of the participating hospitals approved the study, and the cases and controls gave their written informed consent.
This study has been conducted on an already selected MI cohort (2008 white individuals who developed premature MI and an equal number of age-matched and sex-matched controls) collected by the Atherosclerosis, Thrombosis, and Vascular Biology Italian Study Group. 19 The replication study was performed on a second Italian cohort of 1119 patients with CAD and 1075 healthy controls, collected by the Verona Heart Study. 20 For a detailed description of the 2 sample populations, see the online-only Data Supplement.
Mutational Screening
Genomic DNA was purified from venous blood by using the salting-out method, arrayed into 96-well plates, and then amplified with polymerase chain reaction (PCR) by using primer couples designed on the basis of the known sequence of exon 8 of the MEF2A gene (GenBank accession number NM_005587). PCR conditions can be provided on request. All reactions were performed using the Mastercycler EPgradient (Eppendorf AG, Hamburg, Germany). Direct sequencing of PCR products, purified by means of Perfectprep PCR Cleanup 96 kit (Eppendorf), was performed by the fluorescent dideoxy terminator method (BigDye Terminator Cycle Sequencing Ready Reaction Kit version 3.1; Applied Biosystems, Foster City, Calif). Sequencing reactions were purified by the Sequencing Reaction Cleanup Kit Montage SEQ 96 (Millipore, Bedford, Mass) and analyzed by using an ABI-3130XL Genetic Analyzer (Applied Biosystems). The Variant Reporter software was used for mutation detection (Applied Biosystems).
To evaluate the in-cis or in-trans association of Pro279Leu and Pro287Arg mutations in the double heterozygous patient, a PCR fragment containing the mutations was amplified from genomic DNA and cloned into the pTARGET vector by the TA-cloning strategy. 21 Twenty recombinant clones were sequenced.
Site-Directed Mutagenesis
Mutations (⌬21 bp, S235Y, S246G, N263S, P271R, P279L, P279A, and P287R) were inserted in the pcDNA3.1-MEF2A (all mutants), pE-MEF2A-GFP (⌬21 bp), or in the pcDNA3.1-MEF2A-FLAG (⌬21 bp) vector by site-directed mutagenesis, using the Quick-Change Site-Direct Mutagenesis Kit (Stratagene, La Jolla, Calif) and following the manufacturer's instructions. All constructs were checked by sequencing the whole cDNA. Large-scale recovery of plasmid DNA for transient transfection assays was achieved using the GenElute Endotoxin-free Maxiprep plasmid Purification Kit (Sigma), according to the manufacturer's instructions.
Cell Line Cultures and Transfections
The human cervical carcinoma HeLa cell line was cultured in DMEM (EuroClone, Wetherby, United Kingdom) supplemented with 10% fetal bovine serum (HyClone, South Logan, Utah), antibiotics (100 U/mL penicillin and 100 g/mL streptomycin; EuroClone), and glutamine (2 mmol/L; EuroClone), and grown at 37°C in a humidified atmosphere of 5% CO 2 , according to standard procedures.
In each transfection experiment, an equal number of cells (250 000) were transiently transfected with the Lipofectamine 2000 reagent (Invitrogen) in 6-well plates or on glass coverslips, essentially as described by the manufacturer.
Firefly Luciferase and Renilla Luciferase Assays
To analyze the effect of the identified mutations on MEF2A transcriptional activity, we used the luciferase reporter gene under the control of 4 consensus MEF2A response elements. The 4ϫMEF2A-Luc construct (1 g) was cotransfected either with the wild-type or with the mutant pcDNA3.1-MEF2A expression vector (2 g) into HeLa cells. The heterozygous condition (WT/⌬21bp) and the double heterozygous condition (P279L/P287R) were also reproduced cotransfecting equimolar amounts of the relevant plasmids.
Transcriptional activity was assayed by measuring luciferase activity. Because of the variability inherent in transient transfections, data were normalized to an internal control vector (pRL-TK, 100 ng).
The activities of firefly and renilla luciferase were measured 48 hours after transfection by using the Dual-Luciferase Reporter Assay System (Promega). All transfections were performed in duplicate, and each construct was tested in at least 3 independent experiments using different batches of plasmid preparation. The luciferase activity was measured using the microplate reader Wallac 1420 VICTOR 3 V (Perkin Elmer, Waltham, Mass).
For each construct, the values of firefly luciferase obtained in different experiments (expressed as relative luminescent units) were normalized against the corresponding values of renilla luciferase (also expressed as relative luminescent units). Normalization was performed for each sample before making comparisons between test groups.
Immunofluorescence Staining
We expressed wild-type and mutant MEF2A proteins tagged with a FLAG-epitope or C-terminally fused to the GFP protein into HeLa cells and studied the cellular localization of MEF2A directly (by visualizing GFP) or by immunofluorescence staining. Cells grown on glass coverslips were fixed with 4% (weight/volume) paraformaldehyde, incubated with the mouse anti-FLAG M2 antibody followed by Alexa Fluor 568-conjugated antimouse IgG. Coverslips were mounted on glass slides with Moviol and examined under a Zeiss Axioplan microscope with an oil-immersion 40ϫ Neofluar objective (numerical aperture, 1.3) (Zeiss, Oberkochen, Germany). Images were acquired with a Zeiss Axiocam HRM digital camera and then processed using Adobe Photoshop 7.
Microsatellite Analysis
Two putative microsatellite markers (a TG repeat, located Ϸ30 kb upstream of the MEF2A 5ЈUTR, and an ATA repeat, located in MEF2A intron 4) and the trinucleotide repeat (rs3138597, located in MEF2A exon 12) were selected from the University of California Santa Cruz Genome Browser database. MEF2A-CAG-F and MEF2A-TG-R primers were fluorescently labeled with 6-FAM (6-carboxyfluorescein), and MEF2A-ATA-R primer with HEX (4,7,2Ј,4Ј,5Ј,7-hexachloro-6-carboxyfluorescein). PCRs were initially carried out as a single reaction to test for polymorphic content by genotyping 24 healthy Italian individuals. The 3 microsatellite markers were subsequently amplified for genotyping using a 3-plex PCR approach (see online-only Data Supplement). Labeled products were analyzed using an ABI-3130XL Genetic Analyzer and the GeneMapper 4.0 software (Applied Biosystems).
Statistical Analysis
Phenotypic Data
Categorical data were tested for difference between cases and controls by means of a 2 test. Continuous data were tested using the 2-tailed Student t test. Body mass index was analyzed as a quantitative variable, because the test for trend did not reveal any evidence of a statistically significant departure from linearity. All calculations were performed using R software (http://www.r-project.org/).
Genetic Data
The Fisher exact test was applied to monitor the association between the 21-bp deletion and MI. The Fisher exact test was calculated using R.
Allele and genotype frequencies of the 3 microsatellite markers were calculated from the data by using the Genepop program, option 5 (http://genepop.curtin.edu.au/). 22 The same software, option 1, was used to test the deviation from the Hardy-Weinberg equilibrium. The polymorphism information content value for each microsatellite was estimated using R.
Allele and genotype frequencies were compared by means of a 2 statistic, generated through the Monte Carlo approach using the CLUMP program (http://www.mds.qmw.ac.uk/statgen/dcurtis/ software.html). 23 CLUMP uses the Monte Carlo procedure by measuring the differences in frequencies between cases and controls, and then produces multiple simulated datasets to calculate how many times the observed differences might be generated by chance if the frequencies were the same. Significance was assessed for each marker by carrying out 1000 simulations. The use of the Monte Carlo simulation to assess empirical significance avoids the usual asymptotic assumptions that may be inappropriate for markers with rare alleles.
Results
Phenotypic Characteristics of Case-Control MI Cohort
The case sample consisted of 1785 men and 223 women, whose mean age at the time of MI was 39.6Ϯ4.9 years. An equal number (nϭ2008) of sex-matched and age-matched healthy subjects was used as controls. As expected, traditional risk factors were strongly associated with MI ( Table 1 ).
Genotyping of the 21-bp Deletion
To explore the role of MEF2A in the pathogenesis of the disease, all samples were genotyped for the 21-bp deletion. To this purpose, given the close proximity (26 bp upstream) of the deletion to a trinucleotide CAG repeat (rs3138597), coding for a polyglutamine tract (Figure 1 ), both genetic variations were analyzed simultaneously by genotyping the rs3138597 microsatellite marker.
Genotyping revealed 11 different alleles spanning from 4 to 15 CAG repeats ( Table 2 ). The accuracy was Ͼ99% according to random duplicated genotyping of 5% of samples. No significant deviation from Hardy-Weinberg equilibrium was observed either in cases or in controls (or in both). Alleles shorter than 5 repeats were sequenced, revealing the presence of the 21-bp deletion in 5 patients and in none of the controls (Fisher exact test, 2-tailed, Pϭ0.062) (online-only Data Supplement Table II) . ʈHypercholesterolemia was defined by total cholesterol concentration Ͼ5.2 mmol/L or presence of lipid-lowering therapy.
Mutational Screening of Exon 8
A mutational screening of MEF2A exon 8 was performed to evaluate the frequencies of the known mutations (Asn263Ser, Pro276Leu, and Gly283Asp) 11 in the Italian population and to attempt to identify novel genetic defects potentially associated with MI. The MEF2A exon 8 and its intron-exon boundaries were PCR amplified from the genomic DNA of all 4016 samples. Sequence analysis disclosed 2 previously described (Asn263Ser and Pro279Leu) and 5 novel (Ser235Tyr, Ser246Gly, Pro279Ala, Pro271Arg, and Pro287Arg) missense mutations in a total of 5 cases and 5 controls (Figure 1 and online-only Data Supplement Table  II ). The 2 previously reported mutations were common to both groups: the Asn263Ser mutation was identified in 2 patients and in 1 control, whereas the Pro279Leu was identified in 1 patient and in 2 controls. One of these healthy controls is a compound heterozygote for the previously reported Pro279Leu mutation and the novel Pro287Arg one. The in-trans association of the 2 mutations was demonstrated by cloning the relevant PCR fragment into the pTARGET vector.
Functional Characterization of MEF2A Mutant Proteins
To confirm the functional consequences of previously published MEF2A mutations and to demonstrate the possible functional role of newly identified genetic variations, in vitro expression experiments were performed by transiently expressing both the wild-type and the mutant proteins in HeLa cells. Immunolocalization experiments were performed by expressing wild-type and ⌬7aa MEF2A proteins tagged with a FLAG-epitope or C-terminally fused to the GFP protein, and their subcellular distribution was examined by visualizing GFP or by immunofluorescence staining 48 hours after transfection. As shown in Figure 2 , GFP fluorescence stains both the nucleus and the cytoplasm (Figure 2A) , whereas the full-length MEF2A-GFP fusion protein is localized exclu-sively in the nucleus (Figure 2B ), as previously published. 8, 24 The nuclear dye DAPI showed a staining colocalization signal with the MEF2A-GFP fusion protein (data not shown). Unexpectedly, the ⌬7aa MEF2A-GFP is still able to translocate to the nucleus ( Figure 2C ). As control, a MEF2A mutant deleted of the C-terminal 36 amino acids containing the nuclear localization signal (⌬NLS-MEF2A-GFP) 24 was also expressed, showing complete retention in the cytoplasm ( Figure 2D ). Similar results were obtained by expressing FLAG-tagged MEF2A proteins and immunodecorating with an anti-FLAG antibody (data not shown).
The functional effects of all identified mutations were also explored by transcription activation assays. To assess the activity of the MEF2A mutated proteins, a firefly luciferase reporter gene, containing 4 copies of the MEF2 DNA-binding site upstream of a minimal promoter, was cotransfected with wild-type or mutant pcDNA3.1-MEF2A expression constructs, alone or in combination, into HeLa cells. MEF2A transcriptional activity was determined by measuring firefly luciferase activity. After normalization to renilla luciferase activity, values were expressed as fold increase over control (cells expressing the reporter gene only). As shown in Figures  3 and 4 , none of the identified mutations significantly impaired the transactivation activity of MEF2A. As expected, transcriptional activity was completely abolished in the nuclear localization signal-deleted mutant.
Association Study Using Microsatellite Markers
To further elucidate the potential role of MEF2A in the susceptibility to MI, an association analysis was performed on the entire case/control MI cohort by genotyping, besides the aforementioned rs3138597, 2 additional microsatellite markers located in the 5Ј region and in intron 4 of the gene. No significant deviation from Hardy-Weinberg equilibrium was observed in cases or in controls (or in both). Association was tested using the CLUMP program. None of the analyzed markers demonstrated association in the allelic and genotypic analyses, only the T3 statistics (ie, the largest of the 2 statistics of 2ϫ2 tables, each of which compares one allele with the rest grouped together) of the TG-repeat and rs3138597 markers being weakly significant ( Table 2) .
Replication Study in a CAD Cohort
The case sample consisted of 894 men and 225 women, whose mean age at the time of CAD onset was 61.3Ϯ10.0 years, and the control sample consisted of 1075 individuals (mean age, 56Ϯ10.0; 52.1% men). Among these, 390 individuals had angiographically documented completely normal coronary arteries (CAD-free). Table 3 shows the frequency distributions for the traditional risk factors in cases and CAD-free controls. Male sex, body mass index, hypertension, smoking, diabetes, and hypercholesterolemia were all significantly associated with CAD (Table 3) .
No significant allelic/genotypic association between CAD phenotype and the 3 analyzed markers (TG-and ATA-repeat, and rs3138597) could be detected (see online-only Data Supplement Table III ). Moreover, the 21-bp deletion was not observed in any of the 1119 patients with CAD and was identified in a single individual belonging to the control group (a 55-year-old woman, not angiographically tested).
Discussion
The studies investigating the MEF2A association with CAD/MI have been until now inconclusive. First described in 2003, 8 the 21-bp deletion in MEF2A, found in a multiplex CAD family, was claimed as the first gene mutation directly implicated in CAD, suggesting that this condition could be inherited in a Mendelian fashion. Among the 93 predicted genes contained in the linked region, MEF2A was considered a plausible candidate because of its role in the development of heart muscle and of its high level of expression in the endothelium of coronary arteries. 8 Most importantly, its causal role was strengthened by in vitro functional studies showing that both the ⌬7aa deletion and the 3 missense mutations subsequently found in patients either impaired the transcription factor localization to the nucleus or shut down its transactivating activity. 8, 11 In this frame, very recently Wang et al reported at the Scientific Sessions 2007 of the American Heart Association that MEF2A heterozygous knock-out mice (produced in a APOE Ϫ/Ϫ background) showed markedly accelerated atherosclerosis. However, the association of MEF2A with CAD/MI has been challenged by subsequent investigations, because the originally described mutations in MEF2A were observed in unaffected individuals and did not segregate with the disease. 12, 15 The advent of large-scale genome-wide association studies, which pointed out the first consistently replicated CAD/MI loci, 4 -7 showed no significant signal in the 15q26 region. This is not surprising, considering that mutations in the Mendelian counterparts of common disease traits are often nearly family specific, with the relevant gene failing to be involved in the pathogenesis of the disease at a population level. 25 The role of MEF2A in familial MI was recently analyzed by Lieb et al, 18 who performed the most comprehensive analysis on MEF2A to date. They completely screened the gene in 23 cases with familial MI, genotyped the Pro279Leu variant in 533 patients with sporadic MI (versus 2076 controls), and analyzed the CAG repeat in 543 patients with sporadic MI (versus 1190 controls). Mutational screening failed to find the 21-bp deletion, neither was any other pathogenic variant in MEF2A identified. Furthermore, association with 11 single-nucleotide polymorphisms covering the MEF2A gene in 753 cases and 1644 controls excluded that it is a susceptibility gene for MI. However, an evaluation of the frequency of the 21-bp deletion in sporadic cases was lacking. 18 Our work fits into this context: (1) we searched for the 21-bp deletion in a total of 3127 patients with CAD/MI and 3083 healthy controls (it was found in 5 cases and in 1 control individual); (2) we sequenced in 2008 cases with MI and an equal number of controls MEF2A exon 8, in whom all putative causative mutations have been up to now identified (5 novel and 2 previously described missense variations were found); and (3) we performed a microsatellite-based association analysis between the MEF2A locus and CAD/MI (no significant allelic/genotypic association was found). Altogether, our analyses indicate a lack of evidence for a significant association between CAD/MI and MEF2A in the Italian population.
More importantly, we carried out the first replication of functional studies on MEF2A mutations. These experiments were performed in a cellular model on all genetic variants found in the patients with sporadic MI who were analyzed and in their matched controls (ie, the ⌬7aa MEF2A protein and 7 additional missense mutants). In particular, we first tried to replicate immunolocalization experiments of wildtype and ⌬7aa MEF2A proteins, using 2 different approaches (ie, by expressing a FLAG-tagged or a GFP-tagged MEF2A). With both strategies, and unlike the results obtained by Wang et al, 8 we did not find any difference between the wild-type protein and the ⌬7aa MEF2A, the latter retaining its ability to translocate to the nucleus. Second, the functional effects of all identified mutations, also including the ⌬7aa deletion, were explored by transcription activation assays. It must be pointed out that such assays were initially performed using the same reporter system of Wang et al 8 ; however, our experimental conditions did not allow us to discriminate between a true transactivating signal and the baseline noise (data not shown). Instead, the use of a more sensitive reporter system enabled us to demonstrate that the wild-type and all mutant MEF2A proteins display similar levels of luciferase reporter gene activity, again in contrast with the literature data. 8, 11 In conclusion, our association and functional analyses do not support the role of MEF2A in CAD/MI, at least in the Italian population. Only a question remains open: the relevance of the reported association between the MEF2A 21-bp deletion and CAD in the first analyzed family. 8 The chance that a different mutation, located within the relatively large linked region and associated with the deletion, could be responsible for the CAD phenotype should not be overlooked. This hypothesis might reconcile with our finding of the 21-bp deletion in 5 patients with MI and in none of their matched controls.
